Genmab — September 2019
-
1402
-
Det er vel ok..:-)
-
1.402...Vild omsætning i auktionen.
-
Var det lige 300 millioner som blev omsat?
-
Apropo Novo...oms 2,1 mia.. helt vildt!
-
Det blev sgu´en ok dag.
-
Tålmodig nohope..det er kun starten...Novo kommer til at køre klatten i fremtiden.
-
Go´weekend til alle..:-)
-
Nohope...Der har været konsensus om at godkendelsen blot var en formalitet. https://play.borsen.dk/social/5d84327a595ab4f00a335a7e
-
PS: Mon ikke aktien trods alt tager nogle yderligere procenter på mandag?
-
Opdatering af 81186372, hvor det nu er sådan, at Participants will receive IV infusion of JNJ-61186372 as monotherapy at RP2D regimen or in combination lazertinib at RP2CD regimen as determined in Part 1. (Lazertinib is a third generation EGFR tyrosine-kinase inhibitor for NSCLC )
-
J&J buys novel lung cancer drug from South Korea's Yuhan
Janssen Biotech has bought Yuhan’s lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer (NSCLC).
pharmaphorum (pharmaphorum.com)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind